Patients with HER-2 positive early breast cancer with residual invasive disease after neoadjuvant therapy were randomly ...

For patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, adjuvant trastuzumab ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...

Adjuvant ado-trastuzumab emtansine significantly prolonged survival compared with trastuzumab for certain women with ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

In the study, Tukysa (tucatinib) given with Kadcyla (trastuzumab emtansine) improved progression-free survival (PFS) compared to Kadcyla plus placebo, and Seagen plans to submit the data to ...

and Roche's ADC Kadcyla (trastuzumab emtansine), which is sometimes used off-label in this setting. Between 2% and 4% of cases of NSCLC – the most common form of lung cancer, accounting for more ...

It launched Ujvira, (Trastuzumab Emtansine biosimilar) in India, which is the first biosimilar of an Antibody Drug Conjugate (ADC) Kadcyla and a highly effective drug for treatingboth early and ...